You have 9 free searches left this month | for more free features.

Metastatic Cervical Cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cadonilimab in Recurrent or Metastatic Cervical Cancer

Not yet recruiting
  • Recurrent or Metastatic Cervical Cancer
  • (no location specified)
Nov 23, 2023

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy Trial run by the Precigen, Inc (PRGN-2009 plus Pembrolizumab,

Not yet recruiting
  • Cervical Cancer
  • +2 more
  • PRGN-2009 plus Pembrolizumab
  • Pembrolizumab alone
  • Bethesda, Maryland
    National Institute of Health
Nov 27, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Persistent, Recurrent, or Metastatic Cervical Cancer Trial in Shanghai (GLS-010, Placebo, paclitaxel)

Not yet recruiting
  • Persistent, Recurrent, or Metastatic Cervical Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Hospital
Apr 4, 2023

Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +5 more
  • (no location specified)
Apr 9, 2023

Cervical Cancer Trial in Beijing (BL-B01D1, SI-B003)

Not yet recruiting
  • Cervical Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Aug 16, 2023

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

METASTATIC CERVICAL CANCER Trial (QL1706, Placebo)

Recruiting
  • METASTATIC CERVICAL CANCER
  • Chongqing, Chongqing, China
  • +2 more
Nov 24, 2022

Cervical Cancer Trial in Xi'an (Caldonirimab and Nimotuzumab)

Active, not recruiting
  • Cervical Cancer
  • Caldonirimab and Nimotuzumab
  • Xi'an, Shaanxi, China
    The First Affiliated Hospital of Xi'an Jiao Tong University
Oct 31, 2022

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Serplulimab in 2L and Above Treatment of Cervical Cancer

Recruiting
  • Cervical Cancer
  • Jinan, Shandong, China
    Qilu Hospital of Shandong University
May 30, 2023

Recurrent or Metastatic Cervical Cancer Trial in Shanghai (SHR-1210, SHR-1020, Physician's choice chemo)

Active, not recruiting
  • Recurrent or Metastatic Cervical Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 14, 2022

Cervical Cancer Trial in China (Disitamab Vedotin, Zimberelimab)

Not yet recruiting
  • Cervical Cancer
  • Bengbu, Anhui, China
  • +11 more
Nov 23, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Cervical Cancer, Metastatic Cervical Cancer Trial in Washington, Hackensack (Pembrolizumab, Lenvatinib)

Recruiting
  • Cervical Cancer
  • Metastatic Cervical Cancer
  • Washington, District of Columbia
  • +2 more
Jul 26, 2022

HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer Trial (VB10.16, Atezolizumab Injection [Tecentriq],

Not yet recruiting
  • HPV-Related Cervical Carcinoma
  • +2 more
  • VB10.16
  • +2 more
  • (no location specified)
Oct 24, 2023

Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer Trial in Mobile (Cabozantinib 40 MG oral once a day,

Terminated
  • Cervical Cancer
  • +3 more
  • Cabozantinib 40 MG oral once a day
  • Pembrolizumab 200 mg IV every 3 weeks
  • Mobile, Alabama
    University of South Alabama Mitchell Cancer Institute
Jun 3, 2022

Cervical Cancer Trial in Hangzhou (Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin)

Recruiting
  • Cervical Cancer
  • Tislelizumab / Bevacizumab/Paclitaxel/Cisplatin/Carboplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jul 12, 2022

Stage IV Cervical Cancer FIGO 2018, Adenosquamous Carcinoma of Cervix, Cervical Cancer Trial in Dallas (Ultra-fractionated

Recruiting
  • Stage IV Cervical Cancer FIGO 2018
  • +3 more
  • Ultra-fractionated radiation therapy
  • Dallas, Texas
    UT Southwestern Medical Center
Apr 29, 2022

Cervical Cancer Trial in Guangzhou (QL1706)

Recruiting
  • Cervical Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 23, 2022

Cervical Cancer Trial in Miami (Pembrolizumab, Paclitaxel, Cisplatin)

Recruiting
  • Cervical Cancer
  • Miami, Florida
    University of Miami
Oct 1, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Cervical Cancer Trial in Hidaka (Pembrolizumab, Olaparib)

Active, not recruiting
  • Cervical Cancer
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Aug 8, 2022